Consensus Zai Lab Limited Boerse Muenchen

Stocks

1ZL

US98887Q1040

Pharmaceuticals

Market Closed - Boerse Muenchen 23:43:49 11/09/2026 +03			5-day change	1st Jan Change
21.00 ^EUR	0.00%		-7.08%	+40.94%

09-04	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading	MT
09-02	Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT

c07f5ca3d459c34b64b7143a591786.PaqU0tYF0aAn1ZqN4J8B3Su0F7uFZ_HSL1PQ0NZD-Tc.YsempplusMsVjfW4tK0z6QbXbt7RAaeWGhiGoIYZsk1a7OSf4GqomRGY7Q~2d5672179c7a5cb8013bfe8e2a06e987

Analysts' recommendations: Zai Lab Limited

01-07	UBS Initiates Zai Lab at Buy With $35 Price Target	MT
11-05	Zai Lab updates on Amgen's bemarituzumab Phase 1B/3 Fortitude-102 study	RE
11-05	Zai Lab Limited Announces Update on Amgen's Bemarituzumab Phase 1B/3 Fortuda-102 Study	CI
13/03/25	JPMorgan Adjusts Price Target on Zai Lab to $51 From $44, Keeps Overweight Rating	MT
03/03/25	BofA Securities Downgrades Zai Lab to Neutral	MT
12/07/24	JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating	MT
14/12/23	Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target	MT
26/10/23	Citigroup Adjusts Price Target on Zai Lab to $128 From $130, Maintains Buy Rating	MT
26/10/23	Goldman Sachs Lowers Price Target on Zai Lab to $73.34 From $82.47, Maintains Buy Rating	MT
10/08/23	Cantor Fitzgerald Initiates Coverage on Zai Lab With Overweight Rating, $70 Price Target	MT
12/06/23	BofA Adjusts Price Target on Zai Lab to $62.50 From $75, Maintains Buy Rating	MT
11/05/23	Citigroup Adjusts Price Target on Zai Lab to $130 From $138, Keeps Buy Rating	MT
16/03/23	JPMorgan Adjusts Price Target on Zai Lab to $70 From $79, Maintains Overweight Rating	MT
18/11/22	JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating	MT
11/11/22	Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating	MT
09/08/22	Citigroup Adjusts Zai Lab's Price Target to $199 From $193, Reiterates Buy Rating	MT
26/05/22	CSPC Pharma Shares Fall After Weaker 1Q Profit	DJ
12/05/22	Citigroup Adjusts Zai Lab Price Target to $193 From $198, Maintains Buy Rating	MT
11/05/22	SVB Securities Adjusts Zai Lab Price Target to $95 From $101, Maintains Outperform Rating	MT
06/05/22	Guggenheim Adjusts Price Target for Zai Lab to $85 From $134, Maintains Buy Rating	MT
21/04/22	SVB Leerink Adjusts Zai Lab Price Target to $101 From $102, Maintains Outperform Rating	MT
04/04/22	JPMorgan Lowers Zai Lab's Price Target to $112 From $136, Maintains Overweight Rating	MT
03/03/22	Analyst recommendations: Acushnet, Bristol-Myers Squibb, Intel, iQIYI, Polymetal...
02/03/22	SVB Leerink Adjusts Zai Lab Price Target to $102 From $194, Maintains Outperform Rating	MT
04/12/21	Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+8.68%
	CSL LIMITED					+2.83%
	MODERNA, INC.					-16.96%
	SAMSUNG BIOLOGICS CO.,LTD.					+39.05%
	UCB					+38.62%
	BIOGEN INC.					+9.23%
	INCYTE CORPORATION					+5.16%
	INNOVENT BIOLOGICS, INC.					+37.46%
	SWEDISH ORPHAN BIOVITRUM AB					+14.26%
	Average					+15.37%
	Weighted average by Cap.					+13.02%